Elahere is a cancer medicine used for the treatment of adult patients with advanced cancers of the ovaries fallopian tubes (the tubes connecting ovaries to the uterus) and the peritoneum (the membrane lining the abdomen). Elahere can only be used when the cancer cells have receptors (targets) for proteins called folate\-alpha on their surface (folate receptor\-alpha (FRα) positive). It is only used when the cancer has become resistant to platinum\-based cancer treatment. Ovarian cancer is rare, and Elahere was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 19 March 2015\. Elahere contains the active substance mirvetuximab soravtansine.
Therapeutic Indication
Elahere as monotherapy is indicated for the treatment of adult patients with folate receptor\-alpha (FRα) positive, platinum\-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.
Therapeutic Area (MeSH)
ATC Code
L01FX26
ATC Item
N/A
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| mirvetuximab soravtansine | N/A | mirvetuximab soravtansine |
EMA Name
Elahere
Medicine Name
Elahere
Aliases
N/ANo risk management plan link.
